Jain K, Arlin Z, Mertelsmann R, Gee T, Kempin S, Koziner B, Middleton A, Jhanwar S, Chaganti R, Clarkson B
J Clin Oncol. 1983 Nov;1(11):669-76. doi: 10.1200/JCO.1983.1.11.669.
Twenty-eight patients with Philadelphia chromosome (Ph1)--positive and terminal transferase (TdT)--positive acute leukemia (AL) were treated with intensive chemotherapy used for adult acute lymphoblastic leukemia (L-10 and L-10M protocols). Fifteen patients had a documented chronic phase of Ph1-positive chronic myelogenous leukemia preceding the acute transformation (TdT + BLCML) while the remaining 13 patients did not (TdT + Ph1 + AL). An overall complete remission (CR) rate of 71% was obtained with a median survival of 13 months in the responders. Clinical presentation, laboratory data, cytogenetics, response to treatment, and survivals of the two groups of patients are compared. These results appear to be similar, suggesting a common or closely related origin. Since the overall survival of those receiving chemotherapy maintenance is poor, three patients underwent allogeneic bone marrow transplantation (BMT) from histocompatibility leukocyte antigen--matched siblings after they achieved CR. One of them is a long-term survivor (35 + months) with a Ph1-negative bone marrow. New techniques such as BMT should be considered in young patients with a histocompatibility leukocyte antigen--compatible sibling once a CR has been achieved.
28例费城染色体(Ph1)阳性且末端转移酶(TdT)阳性的急性白血病(AL)患者接受了用于成人急性淋巴细胞白血病的强化化疗(L - 10和L - 10M方案)。15例患者在急性转化(TdT + BLCML)之前有记录显示为Ph1阳性慢性粒细胞白血病的慢性期,而其余13例患者则没有(TdT + Ph1 + AL)。缓解者的总体完全缓解(CR)率为71%,中位生存期为13个月。对两组患者的临床表现、实验室数据、细胞遗传学、治疗反应和生存期进行了比较。这些结果似乎相似,提示有共同或密切相关的起源。由于接受化疗维持治疗者的总体生存率较低,3例患者在达到CR后接受了来自人类白细胞抗原匹配同胞的异基因骨髓移植(BMT)。其中1例是长期存活者(35 + 个月),其骨髓为Ph1阴性。一旦达到CR,对于有人类白细胞抗原相容同胞的年轻患者,应考虑采用BMT等新技术。